Related Experiment Video
Updated: May 31, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Catecholaminergic-induced arrhythmias in failing cardiomyocytes associated with human HRCS96A variant overexpression
Peidong Han1, Wenfeng Cai, Yanru Wang
1Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0575, USA.
Insights
The histidine-rich calcium binding protein (HRC) Ser96Ala variant worsens calcium handling in heart cells, increasing the risk of dangerous arrhythmias in failing hearts.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- The histidine-rich calcium binding protein (HRC) Ser96Ala polymorphism is linked to ventricular arrhythmias in dilated cardiomyopathy patients.
- The precise molecular mechanisms underlying this association remain unclear.
Purpose of the Study:
- To investigate the cellular and molecular mechanisms by which the HRC Ser96Ala variant contributes to cardiac arrhythmias.
- To assess the impact of HRC Ser96Ala on calcium handling in cardiomyocytes.
Main Methods:
- Adenoviral expression of wild-type HRC (HRC(WT)) and HRC Ser96Ala (HRC(S96A)) in adult rat ventricular cardiomyocytes.
- Measurement of calcium transients, sarcoplasmic reticulum (SR) calcium content, and SR calcium uptake.
- Assessment of spontaneous calcium release events (sparks and waves).
- Evaluation in a rat model of post-myocardial infarction heart failure.
Main Results:
- HRC(S96A) expression exacerbated HRC(WT)-mediated inhibition of Ca(2+) transient amplitude and decay.
- HRC(S96A) further reduced SR Ca(2+) uptake and increased spontaneous Ca(2+) sparks.
- In failing hearts, HRC(S96A) induced significant disturbances in rhythmic Ca(2+) transients.
Conclusions:
- The HRC Ser96Ala variant impairs cardiomyocyte calcium handling, increasing arrhythmogenic potential.
- This genetic variant promotes arrhythmogenic Ca(2+) waves in stressed, failing hearts.
- Suggests a direct link between the HRC Ser96Ala variant and life-threatening ventricular arrhythmias.
Abstract:
The histidine-rich calcium binding protein (HRC) Ser96Ala polymorphism was shown to correlate with ventricular arrhythmias and sudden death only in dilated cardiomyopathy patients but not in healthy human carriers. In the present study, we assessed the molecular and cellular mechanisms underlying human arrhythmias by adenoviral expression of the human wild-type (HRC(WT)) or mutant HRC (HRC(S96A)) in adult rat ventricular cardiomyocytes. Total HRC protein was increased by ∼50% in both HRC(WT)- and HRC(S96A)-infected cells. The HRC(S96A) mutant exacerbated the inhibitory effects of HRC(WT) on the amplitude of Ca(2+) transients, prolongation of Ca(2+) decay time, and caffeine-induced sarcoplasmic reticulum Ca(2+) release. Consistent with these findings, HRC(S96A) reduced maximal sarcoplasmic reticulum calcium uptake rate to a higher extent than HRC(WT). Furthermore, the frequency of spontaneous Ca(2+) sparks, which was reduced by HRC(WT), was increased by mutant HRC(S96A) under resting conditions although there were no spontaneous Ca(2+) waves under stress conditions. However, expression of the HRC(S96A) genetic variant in cardiomyocytes from a rat model of postmyocardial infarction heart failure induced dramatic disturbances of rhythmic Ca(2+) transients. These findings indicate that the HRC Ser96Ala variant increases the propensity of arrhythmogenic Ca(2+) waves in the stressed failing heart, suggesting a link between this genetic variant and life-threatening ventricular arrhythmias in human carriers.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mechanism of Cardiac Arrhythmias
Cardiomyopathy I: Introduction and Classification
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

